In one paragraphArticle in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Meeri KastinenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.ORCID 0009-0007-0954-5612 Jouni HärkönenDepartment of Pathology, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, Finland.ORCID 0000-0002-1201-4288 Päivi SirniöTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.ORCID 0000-0002-3988-3782 Henna KarjalainenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.ORCID 0009-0008-4694-6703 Ville K ÄijäläTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.ORCID 0009-0005-7664-8027 Vilja V TapiainenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.ORCID 0009-0003-6306-6525 Onni SirkiäDepartment of Environmental and Biological Sciences, University of Eastern Finland, Kuopio, Finland.ORCID 0009-0003-8142-7144 Vesa-Matti PohjanenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.ORCID 0000-0002-4129-4346 Maarit AhtiainenCentral Finland Biobank, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, Finland.ORCID 0000-0002-3263-2307 Olli HelminenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.ORCID 0000-0001-9544-6475 Erkki-Ville WirtaDepartment of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.ORCID 0000-0002-2255-6136 Jukka RintalaTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.ORCID 0000-0003-1865-8444 Sanna MeriläinenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.ORCID 0000-0002-5418-4373 Juha SaarnioTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.ORCID 0000-0002-8443-3625 Tero RautioTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.ORCID 0000-0003-4441-9412 Toni T SeppäläFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere University Hospital, Tampere, Finland.ORCID 0000-0002-4940-3498 Jan BöhmDepartment of Pathology, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, Finland.ORCID 0000-0001-9664-588X Jukka-Pekka MecklinFaculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.ORCID 0000-0003-4895-2249 Anne TuomistoTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.ORCID 0000-0002-9949-1887 Markus J MäkinenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.ORCID 0000-0002-9200-4118 Juha P VäyrynenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.ORCID 0000-0002-8683-2996 Funding
Cancer Foundation Finland 59-5619Cancer Foundation Finland 69-7354Cancer Society of Northern FinlandEmil Aaltosen Säätiö (Emil Aaltonen Foundation) 220257 PFinnish State Research FundingOulu Medical Research FoundationSigrid Juséliuksen Säätiö (Sigrid Jusélius Stiftelse) 230229Sigrid Juséliuksen Säätiö (Sigrid Jusélius Stiftelse) 240241Sigrid Juséliuksen Säätiö (Sigrid Jusélius Stiftelse) 250264Suomen Lääketieteen Säätiö (Finnish Medical Foundation) 6021
6 · The paper itselfAbstract
purposeThe prognostic role of tumor proliferation in colorectal cancer has been unclear, whereas T-cell proliferation has been associated with favorable outcomes. We investigated characteristics and prognostic significance of proliferating tumor and cytotoxic T cells. EXPERIMENTAL
designTwo independent colorectal cancer cohorts comprising 1,839 patients were analyzed using multiplex IHC for MKI67 (Ki-67), CD8, and CK. Densities and spatial localization of MKI67+ and MKI67- cytotoxic T cells and tumor proliferation rate were assessed via digital image analysis. Single-cell RNA sequencing data from 62 colon cancers were used to characterize proliferating and nonproliferating cells.
resultsHigh MKI67+ tumor cell percentage was associated with better cancer-specific survival, an antitumorigenic immune microenvironment, downregulation of epithelial-mesenchymal transition, and upregulation of MYC signaling. In the larger cohort, the multivariable HR for high versus low proliferation rate was 0.60 (95% confidence interval, 0.43-0.83). MKI67+CD8+ T cells exhibited high expression of effector molecules such as GZMB and IFNG and stronger association with favorable prognosis than MKI67-CD8+ T cells. The multivariable HR for high versus low MKI67+CD8+ T-cell density was 0.49 (95% confidence interval, 0.35-0.70). However, spatial analysis of tumor cell-T cell co-localization indicated comparable prognostic significance for both subsets when considering their proximity to tumor cells.
conclusionsTumor cell proliferation is a marker for better prognosis in colorectal cancer. Although proliferating cytotoxic T cells demonstrate stronger prognostic value than nonproliferating cytotoxic T cells, spatial proximity to tumor cells diminishes this difference. These findings provide new insights into the interplay between tumor proliferation, immune response, and patient outcomes in colorectal cancer.
Indexed as
Colorectal NeoplasmsT-Lymphocytes, CytotoxicAgedBiomarkers, TumorCell ProliferationEpithelial-Mesenchymal TransitionFemaleHumansKi-67 AntigenLymphocytes, Tumor-InfiltratingMaleMiddle AgedPrognosisTumor MicroenvironmentBiomarkers, TumorKi-67 AntigenMKI67 protein, human
Identifiers
PMID41201451
PMCPMC12809117
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390